Coşkun 2011.

Methods	A patient report of obsessive‐compulsive symptoms during methylphenidate treatment
Participants	Diagnosis of ADHD: unknown (subtype: combined) Age: 10 years old IQ: normal Sex: female Ethnicity: Turkish Country: Turkey Comorbidity: subsyndromal social and generalised anxiety disorders Comedication: unknown Sociodemographics: unknown
Interventions	Osmotic release oral system methylphenidate, 18 mg/day, 1 year Treatment compliance: unknown Osmotic release oral system methylphenidate, 27 mg/day, 3 + 3 weeks Treatment compliance: unknown
Outcomes	Non‐serious adverse events: Osmotic release oral system methylphenidate, 18 mg/day: decreased appetite and initial headache Osmotic release oral system methylphenidate, 27 mg/day: obsessive‐compulsive symptoms, decreased appetite, facial grimace, nail picking/biting Discontinuation of medication: gradually disappearance of symptoms, still subsyndromal obsessive‐compulsive symptoms Re‐administering of osmotic release oral system methylphenidate, 27 mg/day: mild facial grimace, similar obsessive‐compulsive symptoms. After 3 weeks: Children's Yale‐Brown Obsessive‐Compulsive Scale (CY‐BOCS), total score = 21
Notes	Key conclusions of the study authors: clinicians treating children should be familiar with the emergence and management of these unusual side effects Supplemental information was received through personal email correspondence with the authors in August 2013 (Coşkun 2013d [pers comm])